Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
Company Acquired: <a href="https://smartkarma.com/entities/rain-oncology-inc">Rain Oncology </a>was acquired by Pathos AI, Inc. and ceased to trade as an independent public entity in January 2024. This primer analyzes the company's status and assets leading up to the acquisition.</li>
 <li>
Pivotal Trial Failure: The company's lead asset, milademetan, an MDM2 inhibitor, failed to meet its primary endpoint in the Phase 3 MANTRA trial for dedifferentiated liposarcoma in May 2023, leading to a strategic re-evaluation and significant restructuring.</li>
 <li>
Strategic Pivot to Acquisition: Following the clinical setback, <a href="https://smartkarma.com/entities/rain-oncology-inc">Rain Oncology </a>halted further development of milademetan in liposarcoma, reduced its workforce by 65%, and explored strategic alternatives, culminating in the acquisition by Pathos AI.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Company Acquired: Rain Oncology was acquired by Pathos AI, Inc. and ceased to trade as an independent public entity in January 2024. This primer analyzes the company's status and assets leading up to the acquisition.
  
Pivotal Trial Failure: The company's lead asset, milademetan, an MDM2 inhibitor, failed to meet its primary endpoint in the Phase 3 MANTRA trial for dedifferentiated liposarcoma in May 2023, leading to a strategic re-evaluation and significant restructuring.
  
Strategic Pivot to Acquisition: Following the clinical setback, Rain Oncology halted further development of milademetan in liposarcoma, reduced its workforce by 65%, and explored strategic alternatives, culminating in the acquisition by Pathos AI.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Rain Oncology  (RAIN US) - Oct 2025

United States

Rain Oncology Inc. operates as a clinical stage biotechnology company. The Company develops and produces biomarker-driven small molecule therapeutics for patients with cancer and other related diseases. Rain Oncology serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Rain Oncology (RAIN US) - Oct 2025

Company Acquired: Rain Oncology was acquired by Pathos AI, Inc. and ceased to trade as an independent public entity in January 2024. This...

αSK